US FDA clears first product under new fast-track voucher scheme

The US Food and Drug Administration has approved a US-manufactured version of Augmentin XR (amoxicillin-clavulanate potassium) through its new Commissioner’s National Priority Voucher pilot, completing the review in two months. The decision marks the first use of the accelerated pathway, which aims to support domestic production of essential drugs.

US FDA chief Marty Makary said the move signals a shift toward rebuilding the country’s control of medicine supply chains, adding that the approval will boost resilience at a time of ongoing antibiotic shortages. Amoxicillin has faced seven shortages, while Augmentin XR has had two, according to the agency.

Concerns continue to circulate in Washington around the legal basis and transparency of the voucher scheme. Former Center for Drug Evaluation and Research (CDER) leaders Richard Pazdur and George Tidmarsh separately raised questions about the programme before their departures, with lawmakers Frank Pallone Jr and Bernie Sanders also calling for additional scrutiny last month.